This is a randomized, multi-center, single-use, active-controlled, two-stage open study of episil®. The purpose of this study is to assess the local analgesic effect of episil® in cancer patients suffering from chemotherapy- and/or radiation-induced oral mucositis, which will provide scientific and reliable clinical data in the product registration in China.

Inclusion Criteria:

• Male/female patient 18 years of age;
• Pathological histologic and/or cytological diagnosis of malignant tumor;
• Patients who are suffering from symptomatic oral mucositis (WHO grade 2 or above) during chemotherapy and/or radiotherapy during screening period;
• Patients who are suffering from pain inside the oral cavity caused by oral mucositis, and pain assessment by Likert scale (0-10) results in a score of at least 6 out of 10 during screening period and at enrollment on Day 1;
• Patients undergoing chemotherapy and/or radiotherapy: patients must have received at least one cycle of multiple-cycle chemotherapy regimen and/or have received multiple doses of radiation, prior to the enrollment on Day 1;
• Patients at Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2 and 3; and
• Patients are able to provide written informed consent to participate in the study freely after the nature of the study and disclosure of data has been explained to the patients.